Universal Display remains a 'Buy' despite underperformance with a revised price target of $130/share reflecting increased competition and slower growth. Learn more about OLED stock here.
Tarsus Pharmaceuticals remains a Strong Buy, driven by Xdemvy's robust growth and management's $2B+ peak sales target. Click ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results